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A B S T R A C T
Presented here is a case of human parvovirus B19 (PVB19) induced pure red-cell aplasia (PRCA) in immunocom-
promised patient after orthotopic liver transplantation (OLT). PVB19 is a small, single-stranded DNA whose target cell
is the erythroid progenitor in bone marrow. Manifestations of PVB19 infection vary with the immunologic status of the
patient, ranging from asymptomatic to severe infections and PRCA. Post-transplant PRCA is induced either by immuno-
suppressive agents or PVB19. In the presented case, bone marrow aspiration characterized by the absence of mature
erythroid precursors and detection of PVB19 DNA in blood led to treatment with high-dose intravenous human immu-
noglobulins (IVIG) and subsequent recovery of erythropoiesis. Due to insufficient antibody response in immunocompro-
mised patients, suppression of the PVB19 infection is delayed and repetitive treatments may be administrated in attempt
of reversing PRCA.
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Introduction
Pure red-cell aplasia (PRCA) is a syndrome defined by
the absence of mature erythroid precursors in a bone
marrow. Etiology is heterogeneous, including congenital
and acquired forms. Acquired PRCAmay develop in asso-
ciation with autoimmune disorders, neoplastic disorders,
drugs or as a consequence of chronic infection with hu-
man parvovirus B19 (PVB19)1. The PVB19 target cell is
the erythroid progenitor in bone marrow. Primary infec-
tion is asymptomatic in most of the cases, although acute
infection can result in arthritis or erythema infectiosum
(»fifth« disease) and chronic infection with PRCA in
immunocompromised patients.
PVB19 induced PRCA has been rarely reported after
solid organ transplantation, whereas majority of repor-
ted cases develop after kidney transplantation (KT).
Up till now there have been reported only 8 cases of
PVB19 chronic infection after liver transplantation (LT)
in the literature2. This severe complication usually re-
sponds to high-dose intravenous human immunoglobu-
lins (IVIG) with subsequent recovery of erythropoiesis3,
but relapses are common. Reported here is a case of
PVB19 induced PRCA in immunocompromised patient
after LT with systematic review of the present literature.
Case Report
A 58 years old man with end-stage liver disease due to
alcoholic liver cirrhosis underwent in May 2008 ortho-
topic liver transplantation. His postoperative period was
complicated with right-sided bronchopneumonia and de-
terioration of renal function which led to haemofiltra-
tion. On postoperative day (POD) 12 his renal function
improved and haemofiltration was ceased. His immuno-
suppression consisted of triple regime: mycophenolate
mofetil, cyclosporine and prednisolon. Prophylaxis with
valgancyclovir and trimetoprin-sulfometoxasol was initi-
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ated. During first five weeks after LT a progressive drop
of hemoglobin level to 62 g/L was noticed. Anti--erythro-
cyte antibodies tested negative. Upper GI endoscopy and
colonoscopy revealed no lesions whereas urine sediment
was unremarkable. Serological markers of hepatitis B, as
well as cytomegalovirus (CMV) and Epstein Barr virus
(EBV) DNA and HCV RNA tested negative. Bone mar-
row aspiration revealed normocellular smear with dense
granulopoesis demonstrating all developing stages of gra-
nulocytes, and megakaryocytes with rare giant erythro-
blasts indicating potential infection with Parvoviruses
(Figure 1).
Polymerase chain reaction (PCR) of PVB19 DNA con-
firmed the infection with high viral load (1.83´1013 cop-
ies/mL).
Initial treatment with red blood cell transfusions, fol-
lowed by 10-days course of human immunoglobulins (400
mg per kilogram) was started, followed by recovery of he-
moglobin level up to 115 g/L and sharp decline in viral
load to 1.8´105 copies/mL. Due to mild acute cellular
graft rejection the patient received corticosteroid pulses
after which a rise in viral load up to 4.17´1010 copies/mL
and subsequent drop in hemoglobin level were noticed.
Further treatment with red blood cell transfusions and
two more courses of IVIG resulted in viral load decline
and recovery of hemoglobin levels. During one year fol-
low-up period the patient maintained a low-level viremia
without recurrence of PRCA (Figures 2 and 3).
Discussion
Anemia is a frequent problem after LT, with its heter-
ogeneous etiology it can be presented as hyper-regenera-
tive due to blood loss or haemolysis or hypo-regenerative
due to myelotoxic drugs or infectious agents or combina-
tion of both types. One of hypo-regenerative anemias is a
pure red cell aplasia (PRCA) characterized by the inhibi-
tion of erythropoiesis in bone marrow. It can be heredi-
tary or secondary due to multiple factors such as: drugs,
toxins, infections, anti-EPO antibodies, autoimmune dis-
orders, neoplastic disorders4.
PRCA after solid organ transplantation (SOT) occurs
rarely and it is associated with human PVB19 or myelo-
toxic drugs5–7. Thirty drugs have been implicated as
causative factors in PRCA, but most literature describes
single case reports or case series. Data evaluating possi-
ble mechanisms of drug-induced PRCA are limited, with
the conflicting results8. Immunosuppressive agents such
as mycophenolate mofetil (MMF) and tacrolimus (Tac)
have been implicated the most. MMF is an inhibitor of
guanosine triphosphate synthesis and causes selective
inhibition of B-and T-cell lymphocyte proliferation whe-
reas tacrolimus as calcineurin inhibitor inhibitis T-cell
activation. MMF/Tac induced – PRCA resolves after dis-
continuation or dose reduction. Despite of extensive use
of MMF/Tac no consistent associations between RCA and
MMF/Tac have been found, indicating the complex pa-
thogenesis which presumes qualitative alteration of the
global immunosuppression status and possible broader
antiproliferative effect than its proposed lymphocyte-
-specific effect9–11. Majority of post-transplant PRCA ca-
ses develop after kidney transplantation and only few af-
ter liver transplantation. Contributing to a higher inci-
dence of PRCA after kidney transplantation is a
development of neutralizing autoantibodies against
erythropoietin which is a standard treatment of anemia
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Fig. 1. May-Grünwald-Giemsa stained (1000x). Erythoid hypo-
plasia and the cytopathic effect of parvovirus B19 parvovirus in-
fection of the erythroid progenitor cell. Bone marrow showing gi-
ant erythroblast.
Fig. 2. Hemoglobin levels pre- and post-OLT. Therapy with red
blood cell transfuions and repetitive IVIG cycles (0,4 g per kg) re-
sulted in recovery of erythropoiesis demonstrated by monitoring
hemoglobin levels during 1-year follow-up period.
Fig. 3. Therapy response monitoring the PVB19 DNA viral load
after red blood cell transfusion and IVIG during 1-year follow-
-up period.
in patients with end-stage kidney disease (ESKD)8.
Erythropoietin however, is essential for terminal matu-
ration of erythroid progenitors.
PVB19 is a small, single-stranded DNA non-envel-
oped virus, classified into Parvoviridae which was discov-
ered in 19759,10. The virus is spread by infected droplets,
blood-borne transmission and administration of blood
products11,12. The prevalence in the general population of
IgG anti-PVB19 antibodies ranges between 50% and 70%.
Manifestations of its infection vary with the immuno-
logic status of the host. In an immunocompetent patient
after a short period of viremia, IgM and IgG antibodies
are produced followed by the clearance of virus. PVB19
can cause erythema infectiosum (»fifth« disease) in chil-
dren and acute symmetric polyarthropathy in adults13.
In contrast, immunocompromised patients are unable to
produce an effective antibody response allowing mainte-
nance of viremia and development of severe infections as
well as PRCA. The presumed pathogenesis in develop-
ment of PRCA is its viral tropism and direct cytotoxicity
to erythroid progenitor cells leading to inhibition of
erythropoiesis14.
Therapy with intravenous human immunoglobulins
(IVIG) can be effective in treatment of PVB19 induced
PRCA. IVIG act as neutralizing antibodies against the vi-
rus suppressing the infection when administrated in
high-dose (0.4 g/kg or 1 g/kg per day)15. Such treatment
however may be followed by serious side effects like fe-
ver, headache, myalgia, hypertension and acute renal
failure which were not noticed in our case16.
The duration of the therapy depends on the response
of the patient. Immunosuppressed patients after SOT
are unable to produce an effective antibody response to
the virus and therefore may require repeated courses of
IVIG, delaying the recovery period. In spite of persistent
low-viral load our patient did not recur with PRCA and a
monitoring of viral DNA and hemoglobin level was con-
tinued during whole follow-up period.
PRCA after LT is a rare complication, mainly com-
bined with present immunosuppression or PVB19. Al-
though no persistent treatment strategies for PVB19 in-
duced PRCA are present at the moment, treatment with
red blood cell transfusion in combination with high doses
of IVIG can be effective. Due to insufficient antibody re-
sponse in immunocompromised patients, repetitive treat-
ments may be needed in attempt of controlling the
PVB19 infection and reversing PRCA.
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IZOLIRANA APLAZIJA CRVENE KRVNE LOZE UZROKOVANA INFEKCIJOM
PARVOVIRUSOM B 19 NAKON TRANSPLANTACIJE JETRE
S A @ E T A K
Prikazujemo slu~aj izolirane aplazije crvene krvne loze uzrokovane humanim parvovirus B19 (PVB19) kod imuno-
kompromitiranog bolesnika nakon transplantacije jetre. PVB19 je malen, jednolan~ani DNA virus ~ije je djelovanje
usmjereno na prekursorne eritoidne stanice u ko{tanoj sr`i. Manifestacije PVB19 infekcije su raznolike, te ovise o
imunolo{kom statusu bolesnika, a prezentiraju u rasponu od asimptomatskih do te{kih infekcija i izolirane aplazije
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crvene krve loze. Kod transplantiranih bolesnika uzrok izolirane aplazije crvene krvne loze su imunosupresivni lijekovi
ili PVB19. U prikazanom slu~aju temeljem citolo{ke analize ko{tane sr`i uz karakteristi~ni nedostatak zrelih eritoidnih
prekursora te verifikacijom PVB19 DNA u krvi postavljena je dijagnoza. Bolesnik je lije~en visokim dozama intra-
venskih ljudskih imunoglobulina {to je dovelo do oporavka eritropoeze. Me|utim kod transplantiranih bolesnika, radi
imunosupresivne terapije postoji nedostatan imunolo{ki odgovor stoga je supresija infekcije PVB19 odgo|ena {to zah-
tjeva ustrajnost u terapiji u cilju poku{aja reverzije izolirane aplazije crvene krvne loze.
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